Regeneron Net Cash Flow Investment Acquisitions and Disposals vs Net Cash Flow from Operations Analysis
REGN Stock | USD 962.49 3.81 0.39% |
Trend analysis of Regeneron Pharmaceuticals balance sheet accounts such as Retained Earnings of 28.6 B, Cash of 2.9 B, Non Current Assets Total of 14.3 B or Non Currrent Assets Other of 466.3 M provides information on Regeneron Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Regeneron Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Regeneron Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Regeneron |
About Regeneron Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Regeneron Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Regeneron Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Regeneron Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Regeneron currently owns. An asset can also be divided into two categories, current and non-current.
Regeneron Pharmaceuticals Balance Sheet Chart
Regeneron Pharmaceuticals Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Regeneron Pharmaceuticals uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Regeneron Pharmaceuticals' Non Current Assets Total are very stable compared to the past year. As of the 29th of March 2024, Non Currrent Assets Other is likely to grow to about 466.3 M, while Net Debt is likely to drop (28.5 M). Add Fundamental
Total Assets
Total assets refers to the total amount of Regeneron Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Regeneron Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Regeneron Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Regeneron Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Property Plant And Equipment Net
The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.Most indicators from Regeneron Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Regeneron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.As of the 29th of March 2024, Selling General Administrative is likely to grow to about 2.7 B. Also, Tax Provision is likely to grow to about 584.1 M
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 4.7B | 5.6B | 7.1B | 7.4B | Cost Of Revenue | 2.4B | 1.6B | 883.7M | 927.9M |
Regeneron Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Regeneron Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Regeneron Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 14.8B | 17.2B | 25.4B | 29.2B | 33.1B | 34.7B | |
Total Current Liabilities | 1.8B | 2.8B | 3.5B | 3.8B | 3.4B | 3.6B | |
Total Stockholder Equity | 11.1B | 11.0B | 18.8B | 22.7B | 26.0B | 27.3B | |
Property Plant And Equipment Net | 2.9B | 3.2B | 3.5B | 3.8B | 4.1B | 4.4B | |
Net Debt | (903.9M) | 502M | (185.9M) | (404.5M) | (27.1M) | (28.5M) | |
Retained Earnings | 7.4B | 10.9B | 19.0B | 23.3B | 27.3B | 28.6B | |
Cash | 1.6B | 2.2B | 2.9B | 3.1B | 2.7B | 2.9B | |
Non Current Assets Total | 4.2B | 4.4B | 4.9B | 7.1B | 13.6B | 14.3B | |
Non Currrent Assets Other | 531.8M | 328.9M | 555.2M | (4.7B) | 444.1M | 466.3M | |
Cash And Short Term Investments | 6.5B | 6.7B | 12.5B | 14.3B | 10.8B | 11.4B | |
Net Receivables | 2.7B | 4.1B | 6.0B | 5.3B | 5.7B | 6.0B | |
Common Stock Shares Outstanding | 114.6M | 115.1M | 112.2M | 113.5M | 113.7M | 75.4M | |
Liabilities And Stockholders Equity | 14.8B | 17.2B | 25.4B | 29.2B | 33.1B | 34.7B | |
Non Current Liabilities Total | 1.9B | 3.3B | 3.2B | 2.7B | 3.7B | 3.9B | |
Other Current Assets | 959.3M | 1.2B | 332.4M | 933M | 386.6M | 203.9M | |
Other Stockholder Equity | 3.7B | 102.9M | (173.4M) | (404M) | (1.2B) | (1.1B) | |
Total Liab | 3.7B | 6.1B | 6.7B | 6.6B | 7.1B | 7.5B | |
Total Current Assets | 10.6B | 12.8B | 20.5B | 22.1B | 19.5B | 20.5B | |
Short Long Term Debt Total | 713.9M | 2.7B | 2.7B | 2.7B | 2.7B | 2.8B | |
Other Current Liab | 781.1M | 122.4M | 1.7B | 2.0B | 2.4B | 2.5B | |
Accounts Payable | 418.1M | 475.5M | 564M | 589.2M | 606.6M | 636.9M | |
Property Plant And Equipment Gross | 2.9B | 3.2B | 4.9B | 5.4B | 6.1B | 6.4B | |
Accumulated Other Comprehensive Income | 21.1M | 29.3M | (26.2M) | (238.8M) | (80.9M) | (76.9M) | |
Short Term Investments | 1.6B | 1.4B | 2.8B | 4.6B | 8.1B | 8.5B | |
Inventory | 1.4B | 1.9B | 2.0B | 2.4B | 2.6B | 2.7B | |
Other Liab | 889M | 635.5M | 515.3M | 707.8M | 814.0M | 854.7M | |
Other Assets | 913.3M | 2.8B | 555.2M | 747.6M | 859.7M | 902.7M | |
Property Plant Equipment | 2.9B | 3.2B | 3.5B | 3.8B | 4.3B | 4.5B | |
Current Deferred Revenue | 591.7M | 577.7M | 442M | 547.7M | 458.9M | 481.8M | |
Net Tangible Assets | 11.1B | 11.0B | 18.8B | 21.7B | 25.0B | 26.3B | |
Retained Earnings Total Equity | 7.4B | 10.9B | 19.0B | 23.3B | 26.8B | 28.1B | |
Long Term Debt Total | 713.9M | 2.0B | 2.0B | 2.0B | 2.3B | 2.4B | |
Capital Surpluse | 4.4B | 6.7B | 8.1B | 9.9B | 11.4B | 12.0B | |
Long Term Investments | 3.3B | 3.1B | 6.8B | 6.6B | 5.4B | 3.3B |
Currently Active Assets on Macroaxis
When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for Regeneron Stock analysis
When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Global Correlations Find global opportunities by holding instruments from different markets |
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.03) | Earnings Share 34.81 | Revenue Per Share 122.935 | Quarterly Revenue Growth 0.006 | Return On Assets 0.0849 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.